FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to a pharmaceutical dosed form, which includes the product in the form of a solid dispersion, including N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulphanyl)methyl)propyl)amino)-3-((trifluoromethyl)-sulphonyl)benzosulphonamide or its salt, hydrate or solvate, at least, one pharmaceutically acceptable polymer and, at least, one pharmaceutically acceptable solubiliser.
EFFECT: invention is aimed at the method of manufacturing the pharmaceutical dosed form and application of the dosed form in the treatment of proliferative disorders.
19 cl, 8 dwg, 6 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF BCL-2 FAMILY INHIBITOR | 2010 |
|
RU2711359C2 |
| SOLID DISPERSIONS CONTAINING APOPTOSIS PROMOTING PROTEINS | 2010 |
|
RU2550134C2 |
| ABT-263 CAPSULE | 2010 |
|
RU2550956C2 |
| PHARMACEUTICAL DRUG FORM OF TYROSINE KINASE INHIBITOR FOR PERORAL INTRODUCTION | 2007 |
|
RU2468788C2 |
| STABILISED LIPID PREPARATIVE FORM OF APOPTOSIS PROMOTER | 2010 |
|
RU2530642C2 |
| ABT-263 CRYSTALLINE FORMS AND SOLVATES FOR TREATMENT OF BCL-2 PROTEIN RELATED DISEASES | 2010 |
|
RU2551376C2 |
| SOLID DISPERSIONS, CONTAINING KINASE INHIBITORS | 2011 |
|
RU2566716C2 |
| PHARMACEUTICAL COMPOSITIONS | 2005 |
|
RU2373923C2 |
| MDM2 INHIBITORS AND COMBINATIONS THEREOF | 2016 |
|
RU2740091C2 |
| PHARMACEUTICAL COMBINATIONS FOR TREATING A MALIGNANT TUMOR | 2017 |
|
RU2726367C2 |
